000			02286 a2200661 4500
005			20250515124209.0
264		0	_c20080905
008			200809s 0 0 eng d
022			_a1527-3350
024	7		_a10.1002/hep.22357 _2doi
040			_aNLM _beng _cNLM
100	1		_aPockros, Paul J
245	0	0	_aR1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. _h[electronic resource]
260			_bHepatology (Baltimore, Md.) _cAug 2008
300			_a385-97 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlanine Transaminase _xblood
650	0	4	_aAntiviral Agents _xadministration & dosage
650	0	4	_aCytidine _xanalogs & derivatives
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Resistance, Viral
650	0	4	_aDrug Synergism
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHepacivirus _xenzymology
650	0	4	_aHumans
650	0	4	_aInterferon alpha-2
650	0	4	_aInterferon-alpha _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aNucleosides _xadministration & dosage
650	0	4	_aPolyethylene Glycols _xadverse effects
650	0	4	_aProdrugs _xadministration & dosage
650	0	4	_aRNA, Viral _xantagonists & inhibitors
650	0	4	_aRecombinant Proteins
650	0	4	_aRibavirin _xadverse effects
650	0	4	_aTreatment Outcome
650	0	4	_aViral Load
700	1		_aNelson, David
700	1		_aGodofsky, Eliot
700	1		_aRodriguez-Torres, Maribel
700	1		_aEverson, Gregory T
700	1		_aFried, Michael W
700	1		_aGhalib, Reem
700	1		_aHarrison, Stephen
700	1		_aNyberg, Lisa
700	1		_aShiffman, Mitchell L
700	1		_aNajera, Isabel
700	1		_aChan, Anna
700	1		_aHill, George
773	0		_tHepatology (Baltimore, Md.) _gvol. 48 _gno. 2 _gp. 385-97
856	4	0	_uhttps://doi.org/10.1002/hep.22357 _zAvailable from publisher's website
999			_c18054507 _d18054507